Supplementary Table 1: Correlation analysis between the biomarkers for each
disease sub-site: oropharynx (n=68), larynx (n=30), and all other disease sites
(n=11, oral cavity and hypo pharynx combined). Numbers in bold represent
significant correlations. Correlation by p16 status could not be performed for
the other sub-site category as all samples in this group were p16 negative.
|
Oropharynx |
p16 |
CD44 |
C.MET |
EGFR |
mTOR |
|
CD44
|
-0.200 (p=0.102) |
— |
|
|
|
|
C.MET |
-0.008 (p=0.946) |
-0.049 (p=0.690) |
— |
|
|
|
EGFR
|
-0.093 (p=0.449) |
-0.160 (p=0.193) |
-0.184 (p=0.133) |
— |
|
|
mTOR
|
0.009 (p=0.944) |
0.350 (p=0.003) |
0.161 (p=0.191) |
-0.242 (p=0.047) |
— |
|
GLUT1 |
0.101 (p=0.414) |
0.321 (p=0.008) |
-0.211 (p=0.083) |
0.095 (p=0.442) |
0.205 (p=0.093) |
|
Larynx |
p16 |
CD44 |
C.MET |
EGFR |
mTOR |
|
CD44 |
-0.054 (p=0.775) |
— |
|
|
|
|
C.MET |
0.008 (p=0.965) |
0.156 (p=0.410) |
— |
|
|
|
EGFR |
-0.025 (p=0.896) |
0.088 (p=0.643) |
0.017 (p=0.931) |
— |
|
|
mTOR |
-0.154 (p=0.415) |
0.471 (p=0.009) |
0.169 (p=0.373) |
0.012 (p=0.951) |
— |
|
GLUT1 |
-0.138 (p=0.467) |
0.109 (p=0.566) |
0.101 (p=0.596) |
0.163 (p=0.388) |
0.310 (p=0.095) |
|
Other |
p16 |
CD44 |
C.MET |
EGFR |
mTOR |
|
CD44 |
n/a |
— |
|
|
|
|
C.MET |
n/a |
-0.165 (p=0.627) |
— |
|
|
|
EGFR |
n/a |
0.159 (p=0.640) |
0.197 (p=0.562) |
— |
|
|
mTOR |
n/a |
0.178 (p=0.600) |
0.787 (p=0.004) |
0.176 (p=0.604) |
— |
|
GLUT1 |
n/a |
-0.332 (p=0.319) |
0.8718 (p=0.0005) |
0.233 (p=0.490) |
0.771 (p=0.005) |